Type II NKT cells in inflammation, autoimmunity, microbial immunity, and cancer

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Marrero, Idania ^a   Ware, Randle ^a   Kumar, Vipin ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Autoimmunity; Cancer; CD1d; Inflammation; Innate immunity; Lipids; Neutrophils; Sulfatide

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GLUCOSYLCERAMIDASE; GLYCOLIPID; LYMPHOCYTE ANTIGEN RECEPTOR; LYSOPHOSPHATIDYLCHOLINE; MACROPHAGE INFLAMMATORY PROTEIN 2; PHOSPHOLIPID; SULFATIDE; TOLL LIKE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CORYNEBACTERIUM GLUTAMICUM; CYTOKINE RELEASE; GLUCOSE METABOLISM; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATION; MICROBIAL IMMUNITY; MICROGLIA; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; RECEPTOR BINDING; SHORT SURVEY; TYPE 1 NATURAL KILLER CELL; TYPE 2 NATURAL KILLER CELL;

EID: 84935057166     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00316     Document Type: Short Survey

References (64)

1. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol (2007) 25:297-336. doi: 10.1146/annurev.immunol.25.022106.141711
2. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol (2004) 22:817-90. doi:10.1146/annurev.immunol.22.012703.104608
3. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol (2010) 11(3):197-206. doi:10.1038/ni.1841
4. Arrenberg P, Halder R, Kumar V. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol (2009) 218(2):246-50. doi:10.1002/jcp.21597
5. Kumar V, Delovitch TL. Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology (2014) 142(3):321-36. doi:10.1111/imm.12247
6. Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand J Immunol (2012) 76(3):246-55. doi:10.1111/j.1365-3083.2012.02750.x
7. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol (2013) 13(2):101-17. doi:10.1038/nri3369
8. Zhao J, Weng X, Bagchi S, Wang CR. Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response. Proc Natl Acad Sci U S A (2014) 111(7):2674-9. doi:10.1073/pnas.1323845111
9. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest (2004) 114(10):1379-88. doi:10.1172/JCI23594
10. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol (2007) 28(11):491-6. doi:10.1016/j.it.2007.05.008
11. Kronenberg M, Kinjo Y. Innate-like recognition of microbes by invariant natural killer T cells. Curr Opin Immunol (2009) 21(4):391-6. doi:10.1016/j.coi.2009.07.002
12. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci U S A (2010) 107(24):10984-9. doi:10.1073/pnas.1000576107
13. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med (2004) 199(7):947-57. doi:10.1084/jem.20031389
14. Rhost S, Lofbom L, Rynmark BM, Pei B, Mansson JE, Teneberg S, et al. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur J Immunol (2012) 42(11):2851-60. doi:10.1002/eji.201142350
15. Tatituri RV, Watts GF, Bhowruth V, Barton N, Rothchild A, Hsu FF, et al. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc Natl Acad Sci U S A (2013) 110(5):1827-32. doi:10.1073/pnas.1220601110
16. Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med (2012) 18(7):1060-8. doi:10.1038/nm.2811
17. Maricic I, Girardi E, Zajonc DM, Kumar V. Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. J Immunol (2014) 193(9):4580-9. doi:10.4049/jimmunol.1400699
18. Chang DH, Deng H, Matthews P, Krasovsky J, Ragupathi G, Spisek R, et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood (2008) 112(4):1308-16. doi:10.1182/blood-2008-04-149831
19. Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, et al. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood (2015) 125(8):1256-71. doi:10.1182/blood-2014-09-600270
20. Girardi E, Maricic I, Wang J, Mac TT, Iyer P, Kumar V, et al. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat Immunol (2012) 13(9):851-6. doi:10.1038/ni.2371
21. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, Mallevaey T, et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol (2012) 13(9):857-63. doi:10.1038/ni.2372
22. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med (2001) 193(8):893-904. doi:10.1084/jem.193.8.893
23. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, Barton N, et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med (2011) 208(6):1163-77. doi:10.1084/jem.20102555
24. Kinjo Y, Kitano N, Kronenberg M. The role of invariant natural killer T cells in microbial immunity. J Infect Chemother (2013) 19(4):560-70. doi:10.1007/s10156-013-0638-1
25. Holzapfel KL, Tyznik AJ, Kronenberg M, Hogquist KA. Antigen-dependent versus -independent activation of invariant NKT cells during infection. J Immunol (2014) 192(12):5490-8. doi:10.4049/jimmunol.1400722
26. Roy KC, Maricic I, Khurana A, Smith TR, Halder RC, Kumar V. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol (2008) 180(5):2942-50. doi:10.4049/jimmunol.180.5.2942
27. Subramanian L, Blumenfeld H, Tohn R, Ly D, Aguilera C, Maricic I, et al. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected]. PLoS One (2012) 7(5):e37771. doi:10.1371/journal.pone.0037771
28. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest (2007) 117(8):2302-12. doi:10.1172/JCI31602
29. Halder RC, Jahng A, Maricic I, Kumar V. Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem Res (2007) 32(2):257-62. doi:10.1007/s11064-006-9145-4
30. Maricic I, Halder R, Bischof F, Kumar V. Dendritic cells and anergic type I NKT cells play a crucial role in sulfatide-mediated immune regulation in experimental autoimmune encephalomyelitis. J Immunol (2014) 193(3):1035-46. doi:10.4049/jimmunol.1302898
31. Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology (2011) 140(2):646-55. doi:10.1053/j.gastro.2010.10.003
32. Maricic I, Sheng H, Marrero I, Seki E, Kisseleva T, Chaturvedi S, et al. Inhibition of type I NKT cells by retinoids or following sulfatide-mediated activation of type II NKT cells attenuates alcoholic liver disease. Hepatology (2015) 61(4):1357-69. doi:10.1002/hep.27632
33. Kadri N, Korpos E, Gupta S, Briet C, Lofbom L, Yagita H, et al. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol (2012) 188(7):3138-49. doi:10.4049/jimmunol.1101390
34. Parekh VV, Wu L, Olivares-Villagomez D, Wilson KT, Van Kaer L. Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J Immunol (2013) 190(5):1948-60. doi:10.4049/jimmunol.1201718
35. Kumar V. NKT-cell subsets: promoters and protectors in inflammatory liver disease. J Hepatol (2013) 59(3):618-20. doi:10.1016/j.jhep.2013.02.032
36. Brandl C, Ortler S, Herrmann T, Cardell S, Lutz MB, Wiendl H. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells. PLoS One (2010) 5(5):e10800. doi:10.1371/journal.pone.0010800
37. Yang SH, Lee JP, Jang HR, Cha RH, Han SS, Jeon US, et al. Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury. J Am Soc Nephrol (2011) 22(7):1305-14. doi:10.1681/ASN.2010080815
38. Zeissig S, Blumberg RS. Commensal microbiota and NKT cells in the control of inflammatory diseases at mucosal surfaces. Curr Opin Immunol (2013) 25(6):690-6. doi:10.1016/j.coi.2013.09.012
39. Liao CM, Zimmer MI, Wang CR. The functions of type I and type II natural killer T cells in inflammatory bowel diseases. Inflamm Bowel Dis (2013) 19(6):1330-8. doi:10.1097/MIB.0b013e318280b1e3
40. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 113(10):1490-7. doi:10.1172/JCI19836
41. Fuss IJ, Joshi B, Yang Z, Degheidy H, Fichtner-Feigl S, de Souza H, et al. IL-13Ralpha2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut (2014) 63(11):1728-36. doi:10.1136/gutjnl-2013-305671
42. Liao CM, Zimmer MI, Shanmuganad S, Yu HT, Cardell SL, Wang CR. Dysregulation of CD1d-restricted type ii natural killer T cells leads to spontaneous development of colitis in mice. Gastroenterology (2012) 142(2): 326-34.e1-2. doi:10.1053/j.gastro.2011.10.030
43. Exley MA, Hand L, O'Shea D, Lynch L. Interplay between the immune system and adipose tissue in obesity. J Endocrinol (2014) 223(2):R41-8. doi:10.1530/JOE-13-0516
44. Hams E, Locksley RM, McKenzie AN, Fallon PG. Cutting edge: IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J Immunol (2013) 191(11):5349-53. doi:10.4049/jimmunol.1301176
45. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (2011) 332(6026):243-7. doi:10.1126/science.1201475
46. Maricic I, Sheng H, Marrero I, Seki E, Kisseleva T, Chaturvedi S, et al. Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Hepatology (2015) 61(4):1357-69. doi:10.1002/hep.27632
47. Mathews S, Feng D, Maricic I, Ju C, Kumar V, Gao B. Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. Cell Mol Immunol (2015). doi:10.1038/cmi.2015.06
48. Yanagisawa K, Yue S, van der Vliet HJ, Wang R, Alatrakchi N, Golden-Mason L, et al. Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C. J Viral Hepat (2013) 20(8):556-65. doi:10.1111/jvh.12081
49. Adler M, Taylor S, Okebugwu K, Yee H, Fielding C, Fielding G, et al. Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J Gastroenterol (2011) 17(13):1725-31. doi:10.3748/wjg.v17.i13.1725
50. Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology (2010) 51(6):1998-2007. doi:10.1002/hep.23599
51. Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2009) 21(6):673-80. doi:10.1097/MEG.0b013e32831bc3d6
52. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol (2007) 5(6):405-17. doi:10.1038/nrmicro1657
53. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 73(1):181-92. doi:10.1128/IAI.73.1.181-192.2005
54. Mallevaey T, Zanetta JP, Faveeuw C, Fontaine J, Maes E, Platt F, et al. Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni. J Immunol (2006) 176(4):2476-85. doi:10.4049/jimmunol.176.4.2476
55. Sundell IB, Halder R, Zhang M, Maricic I, Koka PS, Kumar V. Sulfatide administration leads to inhibition of HIV-1 replication and enhanced hematopoeisis. J Stem Cells (2010) 5(1):33-42. doi:jsc.2010.5.1.33
56. Fernandez CS, Kelleher AD, Finlayson R, Godfrey DI, Kent SJ. NKT cell depletion in humans during early HIV infection. Immunol Cell Biol (2014) 92(7):578-90. doi:10.1038/icb.2014.25
57. Kwiecinski J, Rhost S, Lofbom L, Blomqvist M, Mansson JE, Cardell SL, et al. Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway. Infect Immun (2013) 81(4):1114-20. doi:10.1128/IAI.01334-12
58. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut (2009) 58(7):974-82. doi:10.1136/gut.2008.163600
59. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med (1993) 177(1):57-68. doi:10.1084/jem.177.1.57
60. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol (2007) 179(8):5126-36. doi:10.4049/jimmunol.179.8.5126
61. Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol (2014) 5:543. doi:10.3389/fimmu.2014.00543
62. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One (2011) 6(6):e20702. doi:10.1371/journal.pone.0020702
63. Izhak L, Ambrosino E, Kato S, Parish ST, O'Konek JJ, Weber H, et al. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res (2013) 73(5):1514-23. doi:10.1158/0008-5472.CAN-12-2567
64. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood (2008) 111(12):5637-45. doi:10.1182/blood-2007-05-092866